Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scient (MLSS) delivers innovative computer-controlled anesthetic systems designed to improve patient comfort in dental and medical procedures. This dedicated news hub provides real-time updates on the company’s technological advancements, regulatory milestones, and strategic partnerships.
Access authoritative information on MLSS’s global expansion across 25+ countries, product innovations like the CompuDent and CompuMed systems, and financial performance. The curated content serves investors and healthcare professionals seeking to monitor the company’s impact on pain management technology.
Key updates include FDA clearances, clinical trial results, partnership announcements with medical institutions, and market penetration strategies. All content is sourced directly from official company communications to ensure accuracy and timeliness.
Bookmark this page for streamlined access to MLSS’s latest developments, enabling data-driven insights into its role in advancing precision anesthetic delivery worldwide.
Milestone Scientific (NYSE: MLSS) announced its Q2 2022 financial results, reporting revenues of $1.6 million, down from $2.4 million in Q2 2021. A significant decrease in dental sales, particularly in China, and the impact of the Russia-Ukraine conflict contributed to this decline. Gross profit fell to $681,000 (41% of revenue) due to a $430,000 allowance on finished goods. The net loss was $2.9 million, unchanged from the previous year. Despite challenges, Milestone is expanding its CompuFlo® Epidural System and is optimistic about future revenue growth, supported by $11 million in cash and cost reductions.
Milestone Scientific (NYSE:MLSS) announced a conference call scheduled for August 16, 2022, at 8:30 AM ET to discuss its Q2 2022 financial results. The call will cover the company’s corporate progress and other developments. Interested parties can join via telephone or listen to a webcast on their website. An audio replay of the call will be available until August 30, 2022. Milestone Scientific focuses on innovative injection technologies designed for medical, dental, and cosmetic applications, enhancing patient comfort and safety.
Milestone Scientific (NYSE:MLSS) has re-engaged Clinical Technology, Inc. (CTI) as a domestic distributor for the CompuFlo® Epidural System, following its adoption in major hospitals and pain management clinics. This collaboration aims to enhance the rollout of a technology recognized for its safety and economic benefits, including a new CPT code that supports potential reimbursement. The CompuFlo system offers significant cost savings, reducing hospital stay costs by approximately $504 compared to traditional methods.
Milestone Scientific (NYSE:MLSS) announced sales of its CompuFlo® Epidural system to the University of Scranton for use in its student registered nurse anesthesia program. This advanced technology enhances epidural procedures by providing real-time feedback, which can reduce risks associated with needle placement. The company's president emphasized the importance of training the next generation of nurse anesthetists, noting the increasing role they play in the field. Overall, the partnership aims to establish the CompuFlo system as a new standard of care in labor, delivery, and pain management.
Milestone Scientific (NYSE:MLSS) announced a distribution agreement with Hager & Werken to market its STA Single Tooth Anesthesia System in Germany and Austria. This system facilitates painless and precise injections, benefiting both patients and dentists by reducing wait times and complications. Hager & Werken, with its strong history in dental instruments, aims to enhance the adoption of this technology in these key markets, which collectively have over 90 million residents.
Milestone Scientific (NYSE: MLSS) has entered into an exclusive distribution agreement with F&M Feed in Greece for its CompuFlo Epidural System. This partnership aims to enhance the availability of innovative medical devices in the Greek market, where there are over 76,000 childbirths annually. The agreement has already led to the commencement of sales and shipments to Greece, reflecting a strong market opportunity. Both companies believe that this collaboration will improve patient outcomes and optimize medical practices in the region.
Milestone Scientific (NYSE:MLSS) announced the successful commencement of sales for its CompuFlo Epidural disposables at a prominent Southern California medical center recognized for maternity care. This facility is part of a large healthcare system that delivers over 100,000 babies annually. CEO Arjan Haverhals highlighted the company's growing presence in the labor market. Additionally, the AMA has approved a new CPT code for the CompuFlo system, expected to enhance commercialization in various markets, including pain management.
Milestone Scientific (NYSE:MLSS) announced the issuance of a new Category III CPT code by the American Medical Association for its CompuFlo Epidural System. This code, effective January 1, 2023, aims to enhance reimbursement opportunities for epidural procedures. The CPT Editorial Panel validated the technology based on clinical studies, which indicate improved accuracy and reduced complications in pain management. CEO Arjan Haverhals highlighted the potential of this development to accelerate commercial rollout and increase market penetration, especially in the chronic pain segment.
Milestone Scientific (NYSE: MLSS) announced the initiation of sales for its CompuFlo Epidural instrument at a prominent veterinary and academic institution. This follows a successful evaluation of the device in maxillary nerve block procedures in horses. The instrument enhances accuracy in nerve block applications and aims to improve the training of upcoming veterinarians. CEO Arjan Haverhals expressed confidence in the commercialization of their technology across various medical sectors, emphasizing the potential for improved patient outcomes and broad market applicability.
Milestone Scientific (NYSE: MLSS) has appointed Ms. Benedetta Casamento to its Board of Directors. Casamento, a retail consultant with extensive experience in finance and brand management, was previously Chairman and President of Allyke, Inc., and has held top roles at Calypso St. Barth and The Talbots. Her expertise in marketing and operations is expected to bolster Milestone's growth strategies, particularly for its CompuFlo® Epidural and CathCheck™ products. Chairman Leslie Bernhard expressed confidence in her potential contributions to the company’s future.
FAQ
What is the current stock price of Milestone Scient (MLSS)?
What is the market cap of Milestone Scient (MLSS)?
